Led · Series A · Nov 2022

Wesper is an NYC-based provider of a clinical-grade, FDA-cleared platform that delivers the full cycle of sleep therapy to home users. Its sensors and algorithms enable at-home medical diagnosis and ongoing measurement before, during, and after treatment. The platform gives users access to customized, professional guidance from sleep specialists without requiring in-person visits. Wesper offers access to sleep data so that professionals can provide care and grow sleep testing services. The company raised $7.5M in a Series A round led by Ceros Capital Markets. Wesper says it will use the funds to accelerate growth and expand operations. Tatch builds a flexible, lightweight patch that measures respiratory effort, breathing airflow, oxygen levels, body position and other signals overnight to produce the data needed to diagnose sleep disorders. The device is intended as a diagnostic tool rather than a consumer nightly tracker and is designed to connect users with specialists who can interpret results. The company says the sensor can help diagnose sleep apnea, restless leg syndrome, insomnia and some respiratory illnesses. Tatch is gearing up for a pilot program in the next few months, is in early conversations with the FDA about clearance, and is targeting a commercial rollout in early 2021. The startup plans to use new funding to scale its engineering and business teams and aims to double headcount by year’s end. Tatch was part of the Runway Startup program at Cornell Tech.

Participated · Equity · Jun 2022

Cordio Medical develops HearO®, a patient-tailored medical speech processing platform that monitors health conditions via a smartphone app. Its technology uses proprietary true speech signal processing unique to each patient, augmented with machine learning for near real-time monitoring and early detection of condition deterioration. The system continuously learns a patient’s voice to provide personalized, seamless monitoring intended to help physicians prevent deterioration and hospitalization. Cordio raised $18M and plans to deploy the funds to support clinical studies, partnerships, operations, and R&D. Retail and distribution of current and future HearO® versions and clinical operations will be based in Israel and the EU, and the company seeks U.S. market entry in early 2024 pending final FDA approval. Leadership includes CEO Tamir Tal and Chairman Eyal Lifschitz.

Led · Equity · Jun 2022

DermaSensor’s core product is a wireless, handheld optical-spectroscopy device that assesses skin lesions at a cellular level, delivering automated skin-cancer detection for use in primary care settings. Cleared by the FDA via the De Novo pathway in early 2024, it is the only automated skin-cancer detection device available to U.S. primary-care physicians. Since its mid-2024 commercial launch, clinicians have scanned more than 20,000 lesions with the device, and usage is growing at an average quarterly rate of 117%. Published studies report sensitivity between 96-100% and specificity up to 77% for pigmented lesions, performance that has been highlighted in Nature and honored by TIME’s Best Inventions of 2024. The company’s AI training dataset has already grown several-fold beyond the original 2,000 lesions, and management cites approximately 2,000 suspicious cancers detected for referral to dermatology. Beyond the cleared algorithm, DermaSensor has three active pipeline programs that will run on the same hardware. To date the company has attracted $43 million in total investment, supporting both commercial expansion and additional clinical evidence generation.

Participated · Series B · Nov 2021

PathologyWatch operates an end-to-end digital dermatopathology platform that integrates laboratory information systems, scanners, a digital viewer, and EMR reporting to give clinics 24/7 access to digital slides and expert dermatopathologists. The company’s core product streamlines workflows for dermatology clinics and labs, enabling faster diagnoses and broader insurance coverage. PathologyWatch is positioning its platform to improve access and equity in dermatopathology while reducing pathology costs. With the new funding, the company plans further research into skincare diagnostics and AI to enhance its diagnostic capabilities. PathologyWatch is expanding operations nationwide and will add new labs in Texas, Florida, and Arizona to support growing volume. CEO and cofounder Dan Lambert emphasizes the company’s role in digitally transforming dermatopathology and improving patient care. PathologyWatch is a Salt Lake City, UT‑based provider of digital dermatopathology services that offers fully interfaced EMR reporting and around‑the‑clock access to digital slides. The company’s solution gives dermatology clinics, hospitals and laboratories access to top‑tier dermatopathologists and a streamlined clinical workflow that interfaces directly into the EMR. PathologyWatch aims to improve operational efficiency by speeding up workflow and enhance patient outcomes via its expert professional team and partner laboratory services. Led by CEO and co‑founder Dan Lambert, the company has raised over $10M in total capital to date. PathologyWatch plans to use new funding to develop its digital dermatopathology offerings, scale its laboratory system and extend artificial intelligence research across various cancer lines to support larger clients and further technological progress. PathologyWatch builds intuitive, easy‑to‑implement digital dermatopathology solutions that digitize pathology workflows and provide EMR‑integrated reporting and 24/7 access to digital slides. The company offers access to top dermatopathologists and lets clients interpret and bill for cases, with a primary focus on outpatient clinics. PathologyWatch has deployed supervised AI in dermatopathology and reports a live clinical implementation in Australia that can generate full reports. It will use the Series A proceeds to strengthen outreach to dermatology clinics nationwide, including plans to triple its sales force over 12 months, expand marketing, and implement a channel partner strategy. The funding will also support continued development of technology and supervised AI for various cancer lines.